There are 2789 resources available
1060P - Serum metabolomic profiling reveals differences in polyamine and tryptophan metabolites in patients with cutaneous, mucosal and uveal melanoma
Presenter: Maysa Vilbert
Session: ePoster Display
1061P - Safety of cemiplimab for advanced cutaneous squamous cell carcinoma: The Spanish named patient programme
Presenter: Almudena Garcia Castano
Session: ePoster Display
Resources:
Abstract
1092TiP - Investigational (Inv) agents with or without pembrolizumab (pembro) or pembro alone in melanoma (mel): KEYMAKER-U02
Presenter: Reinhard Dummer
Session: ePoster Display
1093TiP - An open-label, multicenter, phase I/II clinical trial of RP1 as a single agent and in combination with nivolumab in patients with solid tumors [IGNYTE]
Presenter: Francesca Aroldi
Session: ePoster Display
1094TiP - A randomized, controlled, open-label, phase II study of cemiplimab as a single agent and in combination with RP1 in patients with advanced cutaneous squamous cell carcinoma [CERPASS]
Presenter: Andrew Haydon
Session: ePoster Display
1095TiP - Daromun, a dermato-oncology drug in development for stage III and IV melanoma and non-melanoma skin cancers: A clinical overview
Presenter: Katharina Kähler
Session: ePoster Display
1102P - The phase III NETTER-1 study of 177Lu-DOTATATE in patients with midgut neuroendocrine tumours: Further survival analyses
Presenter: Philippe Ruszniewski
Session: ePoster Display
1103P - 177Lu-DOTATATE efficacy and safety in functioning neuroendocrine tumors: A joint analysis of phase II prospective clinical trials
Presenter: Alberto Bongiovanni
Session: ePoster Display